Welcome to our dedicated page for Odyssey Health SEC filings (Ticker: ODYY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Odyssey Health, Inc. filings document a Nevada medical technology issuer with OTC-traded common stock and a portfolio centered on medical devices and life-saving medical solutions. Its Form 8-K reports cover material definitive agreements, maintenance-service arrangements, financing facilities, promissory notes, convertible notes, warrants, maturity extensions and related capital-structure disclosures.
The company’s registration and periodic disclosure record also addresses securities offerings, operating and financial results, risk factors, shareholder matters, clinical or regulatory disclosures, and governance matters. These filings provide the formal record for Odyssey Health’s public-company obligations, its financing activity, and changes affecting its medical technology asset base.
Odyssey Health, Inc. (ODYY) Schedule 13G/A shows a significant shareholder position by individual investor Jonathan D. Lutz. He reports beneficial ownership of 7,239,595 shares of Odyssey Health common stock, representing 7.3% of the outstanding class. Lutz, a U.S. citizen, has sole power to vote and dispose of all these shares, with no shared voting or dispositive power. He certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of the company, indicating a passive investment status under the applicable SEC rules.
Odyssey Health, Inc. entered a long-term Maintenance Agreement with Mast Hill Fund under which Odyssey will provide facility services through the first business day of February 2034. Mast Hill or its designee will pay service fees totaling approximately $245,000 per year.
In exchange for these fees, Odyssey issued Mast Hill a $2,262,000 convertible promissory note bearing 10% annual interest and maturing on November 13, 2026, convertible into common stock at 85% of the lowest volume weighted average price over the preceding 10 trading days. Odyssey will remit net service fees to Mast Hill as payments on this note.
Odyssey also signed a Securities Purchase Agreement allowing issuance of a convertible note of up to $25,000,000 in multiple tranches with a 10% original issue discount, implying maximum proceeds of $22,250,000 before costs, convertible on the same 85% VWAP formula. The first $500,000 tranche delivered net proceeds of $437,500 and included Warrants for 1,538,461 shares at $0.001 per share, with a requirement to have an effective registration statement within 60 days of each tranche.
Odyssey Health (OTC: ODYY) filed its annual report for the year ended July 31, 2025. The company remains a development-stage medical products business with no FDA-cleared or approved products and no commercial revenue. Management discloses substantial doubt about its ability to continue as a going concern.
As of July 31, 2025, current liabilities were $7,004,421 against current assets of $49,723, resulting in a working capital deficit of $6,954,698. Net loss allocable to common stockholders was $1,742,691 for the period, and the accumulated deficit reached $62,745,837. The aggregate market value of non‑affiliate equity was $1,770,764 as of January 31, 2025, based on a $0.0215 last sale price. Shares outstanding were 99,853,763 as of October 29, 2025.
The portfolio includes CardioMap (heart monitoring) and the Save‑A‑Life choking rescue device; neither has FDA clearance or approval. Due to funding constraints, Save‑A‑Life is prioritized, while CardioMap development is suspended in the near term. The company reports two employees and plans to rely on third‑party partners for manufacturing and distribution if products are cleared.
Odyssey Health, Inc. entered into a Master Technology and Sub-license Agreement with NeuRX Health, Inc., securing exclusive, worldwide rights to BreastCheck®, a non-invasive test for breast abnormalities. The definitive agreement, managed through subsidiary Odyssey Medical Devices, Inc., is subject to certain closing conditions.
The agreement includes customary representations, warranties, covenants, and mutual indemnification, and contemplates customary ancillary documents at closing. The company highlighted risks tied to development and commercialization timelines, funding needs, and intellectual property protection. On October 16, 2025, Odyssey issued a press release announcing the signing; it is filed as Exhibit 99.1, with the agreement as Exhibit 10.1.
Odyssey Health, Inc. reported that on October 9, 2025 it entered into Amendment No. 6 to its promissory note issued on December 13, 2022 with Mast Hill Fund, L.P.
Under this amendment, the maturity date of the promissory note is extended to April 30, 2026, giving the company more time before the debt comes due. The amendment also deletes Section 4.16 titled “Amortization Payments” in its entirety, while all other terms and conditions of the note remain the same.
Odyssey Health, Inc. entered into a new short-term financing arrangement with a private investor. On October 3, 2025, the company received $100,000 under a one-year promissory note effective as of October 1, 2025, bearing interest at 18% per year. This provides near-term cash to the business but at a relatively high interest cost.
As part of this financing, Odyssey issued the investor a warrant to purchase 100,000 shares of its common stock at an exercise price of $0.10 per share
Odyssey Health, Inc. entered into Amendment No. 10 with LGH Investments, LLC, effective as of July 31, 2025, to modify an existing convertible promissory note. Under this amendment, the maturity date of the note is extended to January 31, 2026, giving the company additional time before the debt becomes due, while all other terms and conditions of the note remain unchanged.
The company has filed the form of Amendment No. 10 to the convertible promissory note as an exhibit, making the detailed terms available for review. This update reflects a negotiated change with a financing partner rather than a new financing arrangement.